EpiBiologics, a leader in tissue-selective extracellular protein degradation, today presented the first preclinical data on its EpiTAC bispecific antibody degrader of c-Met, a potential first-in-class ...

Abstract 1679, under the session ‘Drug Combination Strategies for Cancer Treatment’, showed that APG-2449, a novel focal ...

The potential of computational chemistry to revolutionise cancer treatment in Nigeria represents a paradigm shift in medical ...

Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

The US Food and Drug Administration (FDA) has approved nipocalimab (Imaavy) injection for the treatment of adults and ...

Dizal will also present results from the ongoing Phase I/II study of DZD6008, a 4th generation EGFR TKI with full BBB penetration, in advanced EGFR mutation positive (EGFRm) non-small cell lung cancer ...

Relay Therapeutics, Inc.’s RLAY share price has surged by 5.63%, which has investors questioning if this is right time to sell.

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy ...

Summit Therapeutics' shares dropped 36% after ivonescimab data showed no significant survival benefit. Click to read if SMMT ...